Answers are grounded in this paper and cite their sources.
There are now nine biological disease‐modifying antirheumatic drugs (bDMARDs) available for the treatment of rheumatoid arthritis – seven monoclonal antibodies and two fusion proteins. This article summarises their indications, efficacy, place in therapy and adverse effects.
No takes yet. Share an insight, caveat, or question.
Steve Chaplin (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: